← Eichor
Study identifier: NCT06500273 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Condition: Large B-cell Lymphoma  ·  Sponsor: Allogene Therapeutics

PhasePhase 2
Planned participants250
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.

This description comes directly from the study's public registry record.

Talk to the study team

Allogene Therapeutics, Inc  ·  +1 415-604-5696  ·  clinicaltrials@allogene.com

Always discuss trial participation with your own doctor first.

Locations (77)

Banner MD Anderson Cancer CenterGilbert, Arizona, United StatesRecruiting
Genesis Cancer and Blood InstituteHot Springs, Arkansas, United StatesRecruiting
Alta Bates Summit Medical CenterBerkeley, California, United StatesRecruiting
City of HopeDuarte, California, United StatesRecruiting
Cedars-Sinai Medical CenterLos Angeles, California, United StatesRecruiting
University of California, Los AngelesLos Angeles, California, United StatesRecruiting
University of California, Davis Comprehensive Cancer CenterSacramento, California, United StatesRecruiting
University of California, San DiegoSan Diego, California, United StatesRecruiting
University of California, San FranciscoSan Francisco, California, United StatesRecruiting
Rocky Mountain Cancer CentersDenver, Colorado, United StatesRecruiting
Medical Oncology Hematology ConsultantsNewark, Delaware, United StatesRecruiting
MedStar Georgetown University HospitalWashington D.C., District of Columbia, United StatesRecruiting

+ 65 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06500273